Matches in Wikidata for { <http://www.wikidata.org/entity/Q89493530> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- Q89493530 description "artículu científicu espublizáu en payares de 2019" @default.
- Q89493530 description "im November 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q89493530 description "scientific article published on 13 November 2019" @default.
- Q89493530 description "wetenschappelijk artikel" @default.
- Q89493530 description "наукова стаття, опублікована 13 листопада 2019" @default.
- Q89493530 name "Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies" @default.
- Q89493530 name "Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies" @default.
- Q89493530 type Item @default.
- Q89493530 label "Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies" @default.
- Q89493530 label "Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies" @default.
- Q89493530 prefLabel "Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies" @default.
- Q89493530 prefLabel "Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies" @default.
- Q89493530 P1433 Q89493530-E274E6C1-9C53-489F-996F-940F231FCB4A @default.
- Q89493530 P1476 Q89493530-65903E45-4C39-4CDD-8943-B6381BABE0DB @default.
- Q89493530 P2093 Q89493530-0F034E64-B65C-48DB-9F45-322D88BE080F @default.
- Q89493530 P2093 Q89493530-2EDC4F10-AC2A-4EAC-BC58-599D0FB576D7 @default.
- Q89493530 P2093 Q89493530-3C44E3B1-4E32-4FC0-9FB6-62EA5AFCA801 @default.
- Q89493530 P2093 Q89493530-5F6F9FB7-6C1A-47DC-8A4A-69CEC0500A2D @default.
- Q89493530 P2093 Q89493530-6F6235CC-D384-43E2-A9A4-131A66A3D6FB @default.
- Q89493530 P2093 Q89493530-86E5144C-9219-4179-B595-350846A057EC @default.
- Q89493530 P2093 Q89493530-98B4916A-08FE-4427-863C-A3463850FFB9 @default.
- Q89493530 P2093 Q89493530-C07AAB36-298C-449F-9356-68F295E70BAD @default.
- Q89493530 P2093 Q89493530-D362347D-8B86-4B02-8B26-5C32A90E901F @default.
- Q89493530 P2093 Q89493530-D385A486-7F38-4095-99AF-506EB060D734 @default.
- Q89493530 P275 Q89493530-b93827cd-34b8-4af5-931b-af326bd4875c @default.
- Q89493530 P2860 Q89493530-218FF8FA-2C01-4E62-BD47-02EB38FD18CC @default.
- Q89493530 P2860 Q89493530-42449EC5-C560-4783-AC4B-EBE7B512648E @default.
- Q89493530 P2860 Q89493530-8121F272-1CCB-4F13-B06D-21A982AE2400 @default.
- Q89493530 P2860 Q89493530-AD25DC91-6E8B-447A-BBDF-0D87E434DA89 @default.
- Q89493530 P2860 Q89493530-C3142860-4E1D-4105-A367-D13FF2C73404 @default.
- Q89493530 P2860 Q89493530-C87CCD6A-C50C-4C0D-B4D2-359DD2C41174 @default.
- Q89493530 P2860 Q89493530-CCAA5FBF-0E82-4035-98AD-81CA7C506AC8 @default.
- Q89493530 P2860 Q89493530-EE51D36A-FE89-4C4C-9DB6-34084BC71A75 @default.
- Q89493530 P304 Q89493530-49E4AA97-144B-4C90-A515-39F6212AE9DE @default.
- Q89493530 P31 Q89493530-1EB882D1-2B14-4A57-AF3A-139ACE065056 @default.
- Q89493530 P356 Q89493530-D673464F-D0FB-46B5-BFB7-DEC03DC07232 @default.
- Q89493530 P478 Q89493530-A8292B05-3BFE-4CAA-A33B-22D14D4BE629 @default.
- Q89493530 P50 Q89493530-0D6429F6-3E9C-4C2D-8778-AE515B3942EB @default.
- Q89493530 P50 Q89493530-63CF7B33-C57F-494D-81BD-537032FD330E @default.
- Q89493530 P50 Q89493530-B05828A9-8FC3-4C6D-8884-8429645F5714 @default.
- Q89493530 P577 Q89493530-E6E3E2B8-F2A3-44C3-BEA7-3165B10E9DC9 @default.
- Q89493530 P6216 Q89493530-72d84656-1228-4780-b91f-dd963d867a11 @default.
- Q89493530 P698 Q89493530-AA18FC37-CE62-4B7A-97DA-74F0E3E14ECA @default.
- Q89493530 P932 Q89493530-00B6D345-35EF-434C-B9B4-A6EFE90E97CA @default.
- Q89493530 P356 LCTT.S209231 @default.
- Q89493530 P698 32009824 @default.
- Q89493530 P1433 Q15817882 @default.
- Q89493530 P1476 "Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies" @default.
- Q89493530 P2093 "Alice T Shaw" @default.
- Q89493530 P2093 "Anne-Marie Dingemans" @default.
- Q89493530 P2093 "Dong-Wan Kim" @default.
- Q89493530 P2093 "Fabrice Barlesi" @default.
- Q89493530 P2093 "Mathias Schulz" @default.
- Q89493530 P2093 "Ravindra Gupta" @default.
- Q89493530 P2093 "Sai-Hong Ignatius Ou" @default.
- Q89493530 P2093 "Shirish Gadgeel" @default.
- Q89493530 P2093 "Shiyao Liu" @default.
- Q89493530 P2093 "Vlatka Smoljanovic" @default.
- Q89493530 P275 Q18810331 @default.
- Q89493530 P2860 Q38384492 @default.
- Q89493530 P2860 Q38645064 @default.
- Q89493530 P2860 Q38688150 @default.
- Q89493530 P2860 Q38957939 @default.
- Q89493530 P2860 Q41636404 @default.
- Q89493530 P2860 Q54602410 @default.
- Q89493530 P2860 Q92562120 @default.
- Q89493530 P2860 Q93075388 @default.
- Q89493530 P304 "125-130" @default.
- Q89493530 P31 Q13442814 @default.
- Q89493530 P356 "10.2147/LCTT.S209231" @default.
- Q89493530 P478 "10" @default.
- Q89493530 P50 Q37840097 @default.
- Q89493530 P50 Q89493524 @default.
- Q89493530 P50 Q89493526 @default.
- Q89493530 P577 "2019-11-13T00:00:00Z" @default.
- Q89493530 P6216 Q50423863 @default.
- Q89493530 P698 "32009824" @default.
- Q89493530 P932 "6859466" @default.